✦ LIBER ✦

An open-label study of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in the Chinese population

✍ Scribed by Yang Shen; Zhixiang Shen; Bin Jiang; Jian Hou; Rong Zhan; Lugui Qiu; Daobin Zhou; Jie Jin; Juan Li; Fanyi Meng; Ping Zou; Ting Liu; Jianyong Li; Chun Wang; Depei Wu; Jun Ma

Book ID: 107513259
Publisher: Springer-Verlag
Year: 2009
Weight: 370 KB
Volume: 6
Category: Article
ISSN: 1674-5361
DOI: 10.1007/s11805-009-0394-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of pegylated liposomal

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

✍ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop